Spirometry for diagnosis and therapeutic efficacy evaluation in chronic obstructive pulmonary disease in primary care
https://doi.org/10.18093/0869-0189-2014-0-5-101-110
Abstract
Spirometry is the principal method of diagnosis and evaluation of severity and therapeutic efficacy in patients with chronic obstructive pulmonary disease (COPD). According to the current definition of this disease the main pathophysiological sign of COPD is persistent and generally progres sive airflow limitation. This article will reviews common spirometric parameters used for COPD diagnosis and a diagnostic value of FEV1 / FVC ratio used in absolute values or as the lower limit of its normal range. Spirometry allows detecting pulmonary hyperinflation, particularly using the inspiratory capacity; this possibility is very important but is not widely applied. This is a probable reason of COPD underestimation and late diagnosis. Underestimation of COPD is thought to be due to low spirometry implementation in primary care practice as majority of COPD patients seek medical care in the advanced disease when pulmonary function has already been lost significantly. A great problem for wide implementation of spirometry in general practice is difficulty to learn adequate spirometric testing and interpretation of test results. Notwithstanding a new integral assessment of COPD underlying the current COPD classification spirometric parameters (FEV1 < 50 %pred.) often are the leading criteria to predict a high risk of future exacerbations. Recent data have been demonstrated that early spirometric diagnosis of COPD in primary care is the most effective strategy providing more sufficient therapy results.
About the Authors
Z. R. Aysanov
Federal Institution "Pulmonology Research Institute", Federal Medical and Biological Agency of Russia; Moscow, Russia
Russian Federation
Russian Federation
A. V. Chernyak
Federal Institution "Pulmonology Research Institute", Federal Medical and Biological Agency of Russia; Moscow, Russia
Russian Federation
Russian Federation
E. N. Kalmanova
Federal Institution "Pulmonology Research Institute", Federal Medical and Biological Agency of Russia; Moscow, Russia
Russian Federation
Russian Federation
References
1. Murray C.J.L., Lopez A. D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997; 349 (9064): 1498–1504.
2. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2011. www.gold copd.org
3. Hardie J.A., Buist A.S., Vollmer W.M. et al. Risk of over diagnosis of COPD in asymptomatic elderly neversmokers. Eur. Respir. J. 2002; 20 (5): 1117–1122.
4. Hwang Y.I., Kim C.H., Kang H.R.et al. Comparison of the prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of normal and fixed ratio criteria. J. Korean Med. Sci. 2009; 24 (4): 621–626.
5. Aggarwal A.N., Gupta D., Agarwal R., Jindal S.K. Comparison of the lower confidence limit to the fixedpercentage method for assessing airway obstruction in routine clinical practice. Respir. Care. 2011; 56: 1778–1784.
6. Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003; 58: 659–664.
7. Chernyak A.V., Avdeev S.N., Pashkova T.L., Aysanov Z.R. Bronchodilator test in patients with chronic obstructive pulmonary disease. Pul'monologiya. 2003; 1: 51–56 (in Russian).
8. O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542–549.
9. Casanova C., Cote C., de Torres J.P. et al. Inspiratorytoto tal lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 591–597.
10. Hill K., Goldstein R.S., Guyatt G.H. et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. Can. Med. Ass. J. 2010; 182 (7): 673–678.
11. Walters J. A., Haydn Walters E., Nelson M. et al. Factors associated with misdiagnosis of COPD in primary care. Prim. Care Respir. J. 2011; 20 (4): 396–402.
12. Bourbeau J., Sebaldt R.J., Day A. et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: The CAGE Study. Can. Respir. J. 2008; 15 (1): 13–19.
13. Siafakas N.M., Vermeire P., Pride N.B. et al. Optimal assess ment and management of chronic obstructive pulmonary disease (COPD). Eur. Res. J. 1995, 8 (8): 1398–1420.
14. Burdon J.G.W., Pain M.C.F., Rubinfeld A.R., Nana A. Chronic lung disease and the perception of breathlessness: a clinical perspective. Eur. Respir. J. 1994; 7 (7): 1342–1349.
15. van den Boom G., van Schayck C. P., Ruttenvan Molken M. P. M. H. et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population: results and economic consequences of the DIMCA program. Am. J. Respir. Crit. Care Med. 1998; 158 (6): 1730–1738.
16. Sutherland E.R., Cherniack R.M. Management of chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2689–2697.
17. Holleman D.R. Jr, Simel D.L. Does the clinical examination predict airflow limitation? J. Am. Med. Ass. 1995; 273 (4): 313–319.
18. Melbye H., Aaraas I., Hana J., Hensrud A. Improving pulmonary auscultation as a tool in the diagnosis of bronchial obstruction – results of an educational intervention. Scan. J. Prim. Hlth Care. 1998; 16 (3): 160–164.
19. Kaplan A. Systems for the management of respiratory disease in primary care – an international series: Canada. Prim. Care Respir. J. 2008; 17 (2): 73–78.
20. Glasgow N. Systems for the management of respiratory disease in primary care – an international series: Australia. Prim. Care Respir. J. 2008; 17 (1): 19–25.
21. Aisanov Z., Lai C., Bauerle O. et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Inter. J. COPD. 2012; 7: 1–12.
22. Saad N., Sedeno M., Metz K., Bourbeau J. Early COPD Diagnosis in Family Medicine Practice: How to Implement Spirometry? Inter. J. Fam. Med. 2014; 2014: 1–6.
23. Schermer T.R.J., Verweij E.H.A., Cretier R. et al. Accuracy and precision of desktop spirometers in general practices. Respiration. 2012; 83 (4): 344–352.
24. Schermer T.R.J., Crockett A.J., Poels P.J.P. et al. Quality of routine spirometry tests in Dutch general practices. Br. J. Gen. Pract. 2009; 59 (569): e376–e382.
25. Jones R.C.M., DicksonSpillmann M., Mather M.J.C. et al. Accuracy of diagnostic registers and management of chron ic obstructive pulmonary disease: the Devon primary careaudit. Respir. Res. 2008; 9: art. 62.
26. Chavez P.C., Shokar N.K. Diagnosis and management of chronic obstructive pulmonary disease (COPD) in a primary care clinic. J. COPD. 2009; 6 (6): 446–451.
27. Agusti A., Edwards L.D., Celli B. et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur. Respir. J. 013; 42: 636–646.
28. Szafranski W., Cukier A, Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21:74–81.
29. Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912–919.
30. Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide / formoterol added to tiotropiumin patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 741–750.
Review
For citations:
Aysanov Z.R., Chernyak A.V., Kalmanova E.N. Spirometry for diagnosis and therapeutic efficacy evaluation in chronic obstructive pulmonary disease in primary care. PULMONOLOGIYA. 2014;(5):101-110. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-5-101-110
Views:
16660
Email this article 